CG
NVO

Colony Group’s Novo Nordisk NVO Stock Holding History

Colony Group’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		$3.25M Sell
35,781
-385
-1% -$33.9K 0.05% 270
2023
Q2 		$2.93M Sell
36,166
-186
-0.5% -$15.2K 0.04% 285
2023
Q1 		$2.89M Sell
36,352
-5,846
-14% -$415K 0.04% 292
2022
Q4 		$2.86M Buy
42,198
+11,018
+35% +$646K 0.04% 315
2022
Q3 		$1.55M Buy
31,180
+8,930
+40% +$478K 0.03% 365
2022
Q2 		$1.24M Buy
22,250
+5,920
+36% +$329K 0.02% 412
2022
Q1 		$907K Buy
16,330
+1,294
+9% +$66.4K 0.01% 503
2021
Q4 		$842K Sell
15,036
-2,644
-15% -$143K 0.01% 483
2021
Q3 		$849K Buy
17,680
+4,884
+38% +$236K 0.02% 455
2021
Q2 		$536K Sell
12,796
-166
-1% -$6.43K 0.01% 510
2021
Q1 		$437K Buy
12,962
+2,240
+21% +$79.8K 0.01% 561
2020
Q4 		$374K Sell
10,722
-1,170
-10% -$40.4K 0.01% 557
2020
Q3 		$413K Buy
11,892
+2,192
+23% +$73.1K 0.01% 506
2020
Q2 		$318K Sell
9,700
-2,110
-18% -$67.3K 0.01% 542
2020
Q1 		$355K Buy
11,810
+3,960
+50% +$118K 0.01% 522
2019
Q4 		$227K Buy
+7,850
New +$217K 0.01% 692
2019
Q3 		– Sell
-8,366
Closed -$214K – 719
2019
Q2 		$214K Buy
+8,366
New +$207K 0.01% 685
2015
Q4 		– Sell
-140
Closed -$4K – 867
2015
Q3 		$4K Buy
+140
New +$3.96K ﹤0.01% 713
2015
Q2 		– Sell
-1,746
Closed -$47K – 765
2015
Q1 		$47K Sell
1,746
-1,164
-40% -$26.8K 0.01% 434
2014
Q4 		$62K Buy
2,910
+1,164
+67% +$26K 0.01% 421
2014
Q3 		$42K Buy
1,746
+620
+55% +$14.3K ﹤0.01% 443
2014
Q2 		$26K Buy
1,126
+16
+1% +$353 ﹤0.01% 399
2014
Q1 		$25K Sell
1,110
-1,510
-58% -$32.2K ﹤0.01% 411
2013
Q4 		$48K Sell
2,620
-13,580
-84% -$237K 0.01% 324
2013
Q3 		$274K Sell
16,200
-850
-5% -$14.3K 0.05% 132
2013
Q2 		$264K Buy
+17,050
New +$284K 0.05% 129

Other funds holding NVO

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fayez Sarofim & Co
Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Colony Group's NVO Position: Q3 2023 in Review

Colony Group reduced its Novo Nordisk (NVO) stake by 1.1% in Q3 2023, selling an estimated $33.9K and leaving 35,781 shares worth $3.25M. The position accounts for 0.05% of the portfolio, ranked #270.

Colony Group first reported a position in NVO in Q2 2013 and has held it in 26 quarters since. 1,308 funds tracked by Wall St. Rank hold NVO as of Q3 2023.

  • Colony Group held 35,781 shares of Novo Nordisk worth $3.25M as of Q3 2023.
  • Colony Group sold 385 Novo Nordisk shares in Q3 2023, an estimated $33.9K.
  • Novo Nordisk made up 0.05% of Colony Group's portfolio in Q3 2023, its #270 holding.
  • Colony Group first reported a position in Novo Nordisk in Q2 2013 and has held it in 26 quarters since.
  • 1,308 funds tracked by Wall St. Rank held Novo Nordisk as of Q3 2023.

Based on Colony Group's 13F filing for Q3 2023, filed 14 Nov 2023.